ライフサイエンスコーパス: iloprost

1 ayed a distinct sensitivity to cicaprost and iloprost.

2 aspirin, MRS-2179 (a P2Y(1) inhibitor), and iloprost.

3 nd without the prostacyclin receptor agonist iloprost.

4 , similar to the effect of the PGI(2) analog iloprost.

5 rial hypertension (PAH) treated with inhaled iloprost.

6 esence of 4.8 microM pentoxyfilline or 80 nM iloprost.

7 filline and a 10% increase when treated with iloprost.

8 sed Fzd9 expression and prevents response to iloprost.

9 sal levels of ERK phosphorylation induced by iloprost.

10 were blocked by the MEK inhibitor, U0126, or iloprost.

11 hile dose-dependent NO release was evoked by iloprost.

12 low-dose, continuous intravenous infusion of iloprost (0.075 microg/kg/min) or an equivalent volume o

13 randomized to receive a constant infusion of iloprost (0.18 microg/kg/min) or an equivalent amount of

14 Exposure of transfected cells to iloprost (1 microM) for increasing times induced a rapid

15 Iloprost (1 microM, 10 min) desensitized HAhIP- and S374

16 in (mUW); mUW+adenosine (1.34 g/L), and mUW+ iloprost (10(-8)mol/L), a prostacyclin analogue.

17 nts (59%) received active therapy (101 [15%] iloprost, 118 [18%] sitaxsentan, 204 [31%] sildenafil, a

18 randomized to receive a constant infusion of iloprost (20 ng/kg per minute) or an equivalent amount o

19 tagged hIP (hIP1D4) wild-type control (K(i), iloprost = 3 +/- 2 versus 7 +/- 3 nM, respectively).

20 ed, multicenter, double-blind trial, inhaled iloprost (5 mug) or placebo was added to stable monother

21 Fifteen of these treated patients (8 iloprost, 7 placebo) failed to complete all of the follo

22 e in intracellular levels of cAMP induced by iloprost (a prostaglandin I2 analog).

23 capability as compared with control hMSCs or iloprost (a stable PGI2 analogue).

24 Iloprost (a stable prostaglandin I2 analog) -induced ris

25 ion of pial arteriolar responses to ET-1 and iloprost, a cAMP-dependent dilator, in vivo, plus the ef

26 Additionally, we identified Iloprost, a prostacyclin analog, which initiates downstr

27 Treatment of COX-2-deficient PASMCs with iloprost, a prostaglandin I(2) analog, and prostaglandin

28 Conversely, iloprost, a stable analog of PGI(2), augmented IL-17 pro

29 hypoxia or adenosine, but not that evoked by iloprost, a stable analogue of prostacyclin (PGI(2)), or

30 Both PGE2 and iloprost, a stable PGI2 analog, evoke human umbilical ve

31 erns in human platelets after treatment with iloprost, a stable prostacyclin analog, for 0, 10, 30, a

32 Iloprost administration blocked CTGF induction in treate

33 hat, although the stable prostacyclin analog iloprost alone had no effect on the intracellular calciu

34 Iloprost alone induced Id1 expression in human pulmonary

35 Iloprost also attenuated the sustained activation of ERK

36 hundred fifty seven were assigned to receive iloprost and 151 to receive placebo.

37 ic effects of prostacyclin analogues such as iloprost and carbaprostacyclin.

38 ostaglandin E2 (PGE2) and the PGI2 analogues iloprost and carbaprostacyclin.

39 Iloprost and cicaprost also suppressed LPS-induced expre

40 +/- 3.6 pmol/mg protein; n = 4) affinity for iloprost and coupled to both cAMP (EC50 = 0.1 +/- 0.03 n

41 agonists (ADP, convulxin, thrombin, U46619, iloprost and GSNO used at 0.1, 1, and 10xEC50; 154 condi

42 se with KT 5720 reversed the effects of both iloprost and milrinone.

43 date biomarkers for precision application of iloprost and monitoring of treatment progress.

44 lls responded only to high concentrations of iloprost and N(7),N(78)-Q(7),Q(78) were unresponsive.

45 In addition, iloprost and treprostinil enhanced BMP-induced phosphory

46 tion and time of exposure to the PGI2 analog iloprost and was blocked by both RO3244794 and PKA knock

47 on and time of exposure to the PGI(2) analog iloprost and was blocked by both RO3244794 and PKA knock

48 re the inhaled prostanoids (prostacyclin and iloprost), and there is growing interest in novel therap

49 subcutaneously infused treprostinil, inhaled iloprost, and oral beraprost.

50 S328A and S328A/S374A showed a markedly less iloprost- and no PMA-induced phosphorylation.

51 HAhIP and S374A underwent iloprost- and PMA-induced phosphorylation (1 and 5 micro

52 prove blood flow in vivo (pentoxyfilline and iloprost) are shown to increase both the release of RBC-

53 either a continuous intravenous infusion of iloprost at 0.075 microg/kg/min (n = 6) or an equal volu

54 Oral iloprost at a dosage of 50 microg twice daily is no bett

55 PGI2 or iloprost at the IP receptor inhibited basal ERK phosphor

56 lammation suggest that PGI2 and its analogue iloprost, both Food and Drug Administration-approved dru

57 The effects of iloprost, carbaprostacyclin, and treprostinil on the reg

58 Inhaled iloprost caused sustained functional improvement in some

59 We report that PGI(2) analogs (iloprost, cicaprost, treprostinil) differentially modula

60 To investigate the relationship between iloprost, cigarette smoke, and Fzd9 expression, we used

61 ilator responses, elicited by acetylcholine, iloprost, cromakalim, and elevated [K+], were greatly di

62 Iloprost delayed the time to clinical worsening (p = 0.0

63 On the basis of the observation that iloprost did not alter thapsigargin stimulation of Ca(2+

64 Postburn administration of iloprost did not improve the hepatic arterial hemodynami

65 The concept that iloprost does not directly modulate calcium entry was fu

66 ving long-term iloprost therapy, 36% stopped iloprost, due to lower airway reactivity, clinical deter

67 Pretreatment with intravenous iloprost effectively increased intestinal blood flow in

68 Iloprost failed to reverse PPARdelta siRNA-induced impai

69 Iloprost failed to suppress AM functions to the same deg

70 Several studies show efficacy of intravenous iloprost for severe Raynaud's and skin ulcers, and of bo

71 e baseline levels in animals pretreated with iloprost (from 363 +/- 85 to 485 +/- 81 mL/min).

72 One hundred forty-three patients in the iloprost group (91.1%) and 144 in the placebo group (95.

73 e daily frequency of attacks was 1.02 in the iloprost group and 0.83 in the placebo group (P = 0.459)

74 ty of RP attacks, was reduced by 1.32 in the iloprost group and 1.00 in the placebo group (P = 0.323)

75 events occurred in 10 patients (6.4%) in the iloprost group and 3 (2.0%) in the placebo group (P = 0.

76 aseline to week 5-6 was 24.32 minutes in the iloprost group and 34.34 minutes in the placebo group (P

77 fter the tamponade (422 +/- 87 mL/min in the iloprost group vs. 232 +/- 111 mL/min in the control gro

78 At Week 12, patients receiving iloprost had a mean increase in 6-MWD of 30 m (p = 0.001

79 Since low-dose iloprost had no effect on mean arterial pressure, it may

80 Inhaled iloprost has been approved for the treatment of adults w

81 Only during the postburn endotoxic phase, iloprost improved hDO2 and hVO2 (140% and 79%, respectiv

82 udy demonstrate that the addition of inhaled iloprost in patients with PAH with reduced exercise capa

83 enous bradykinin, inhaled NO, or intravenous iloprost in reducing right ventricular systolic pressure

84 ase in RBC-derived ATP was also measured for iloprost-incubated RBCs in flow (362 +/- 45 nM ATP).

85 Stimulation of transfected cells with iloprost induced a rapid time- and concentration-depende

86 Iloprost induced a time- and concentration-dependent los

87 nduced a rapid desensitization of subsequent iloprost-induced (1 microM) HAhIP and S374A adenylyl cyc

88 Thus, cerebral hematoma appears to attenuate iloprost-induced dilation and reduce basal cAMP level 4

89 Iloprost-induced dilation was attenuated by hematoma to

90 sal phosphorylation and dramatically reduced iloprost-induced HAhIP phosphorylation.

91 Deletion of the C terminus prevented iloprost-induced internalization, demonstrating the crit

92 Iloprost-induced sequestration of HAhIP-GFP, followed in

93 These data suggest that iloprost induces apoptosis via a cAMP-mediated suppressi

94 Iloprost infusion increased SMA blood flow by 60% in thi

95 The effect of iloprost infusion was more prominent after the tamponade

96 Acute iloprost inhalation reduced forced expiratory volume in

97 ndard lung function testing before and after iloprost inhalation, 6-min walk test, World Health Organ

98 ++Cicaprost and iloprost inhibit DNA synthesis and proliferation to a gr

99 We found that iloprost inhibited IFN-gamma- and IL-6-induced MCP-1, IL

100 duced MCP-1 production and demonstrated that iloprost inhibited STAT1 activation by several actions a

101 activation by several actions as follows: 1) iloprost inhibited the phosphorylation of STAT1-S727 in

102 In this study, the mechanisms by which iloprost interacts with calcium signaling pathways stimu

103 Acute administration of inhaled iloprost lowered mean pulmonary artery pressure equivale

104 tes IFN-gamma-signaling, was not involved in iloprost-mediated inhibition of STAT1, indicating diverg

105 e therapies using either Wnt7a or its mimic, Iloprost, might represent a new class of therapeutic tre

106 in some children with PAH, although inhaled iloprost occasionally induced bronchoconstriction.

107 d attenuation of pial arteriolar dilation to iloprost on day 4 (14%, 21% and 29% at 10(-12) M, 10(-10

108 We evaluated the acute effects of inhaled iloprost on hemodynamic status and lung function and the

109 lar inflammation, we examined the effects of iloprost on IFN-gamma- and IL-6-stimulated cytokine prod

110 Hx treated rats to investigate the effect of Iloprost on oval cell response.

111 The infusion with iloprost or carrier solution was continued for the durat

112 lone on day 1 did not affect the dilation to iloprost or constriction to ET-1, 4 days later.

113 When iloprost or milrinone was introduced after the initial m

114 Pericardial fluid was then removed, and iloprost or normal saline infusion was continued for ano

115 ericardial tamponade was induced, during the iloprost or normal saline infusion with pericardial tamp

116 imals were randomized to receive intravenous iloprost or normal saline.

117 Infusion of iloprost or saline was continued after pericardial tampo

118 of COX-1 were rescued by the treatment with iloprost or the selective peroxisome proliferator-activa

119 elaxation responses to sodium nitroprusside, iloprost, or the K(+) channel activators (NS1619 and bim

120 omly assigned to receive either 50 microg of iloprost orally twice daily or an identical gelatin-coat

121 in the seventh transmembrane domain enhanced iloprost potency approximately 100-fold.

122 a 2-hr storage, beta-NTP regeneration in mUW+iloprost produced +57.7% (P<0.01) more beta-NTP, at a fa

123 PKA by injection of the prostacyclin analog iloprost reduced PAK activation and inflammatory gene ex

124 Under basal conditions, U0126 or iloprost reduced the number of viable cells and increase

125 rmer smokers using the prostacyclin analogue iloprost reduces endobronchial dysplasia, a premalignant

126 Iloprost requires the presence of the WNT receptor Frizz

127 Furthermore, iloprost rescued the deficit in Smad1/5 phosphorylation

128 % for RBCs incubated with pentoxyfilline and iloprost, respectively.

129 In a randomized and controlled trial, iloprost resulted in improvement in a combined end point

130 lial-derived prostacyclin, we determined how Iloprost reverses ADP-mediated signaling events.

131 tylase and coactivator CBP/p300 to STAT1; 2) iloprost selectively inhibited activation of JAK2 but no

132 f the mutant receptors by PGE2 (EP2 ligand), iloprost (stable prostacyclin analog), and PGE1 (EP2/IP

133 inhibitor milrinone mirrored the actions of iloprost, suggesting that the prostacyclin analog exerte

134 demonstrate an inverse regulation by ADP and Iloprost, suggesting that these are central modulators o

135 7 nm) was evident at those concentrations of iloprost that induce PKC-dependent desensitization.

136 Inhaled iloprost therapy may provide selectivity of the hemodyna

137 nt of patients continued receiving long-term iloprost therapy, 36% stopped iloprost, due to lower air

138 y provides new information on the ability of iloprost to primarily attenuate inositol-1,4,5-triphosph

139 In contrast, iloprost-treated animals did not show hepatic arterial v

140 Portal hypertension did not occur in iloprost-treated animals, as portal venous pressure rema

141 e cardiac output returned to baseline in the iloprost-treated group but remained decreased in the con

142 44 +/- .23) in the control group than in the iloprost-treated group.

143 Postburn iloprost treatment yielded a significant improvement in

144 channels by BAY-K 8644 was unchanged during iloprost treatment.

145 l pressure was not affected by the dosage of iloprost used in this experiment.

146 NYHA status improved by one class in 34% of iloprost versus 6% of placebo patients (p = 0.002).

147 The inhibition of CTGF induction by Iloprost was associated with a significant decrease in o

148 inally, a known inhibitor of CTGF synthesis, Iloprost, was administered to 2-AAF/PHx treated rats to

149 oned from intravenous prostanoids to inhaled iloprost, which continued during follow-up.

150 otein phosphorylation in response to ADP and Iloprost, which inversely overlap and represent major ac

151 resulted in a selective gain of function for iloprost, which is consistent with the proposed phylogen

152 Coadministration of iloprost with AngII attenuated both the immediate peak (

153 ependently dilated to topical application of iloprost with increases in diameter of 10%, 16% and 21%